June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
The ARMS2 insertion/deletion leads to systemic upregulation of secreted HTRA1 levels in the blood in AMD patients
Author Affiliations & Notes
  • Yang Pan
    Director of Molecular and Cellular Biology Division, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
  • Akiko Suga
    Director of Molecular and Cellular Biology Division, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
  • Toru Noda
    Division of Ophthalmology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
  • Inderjeet Kaur
    L. V. Prasad Eye Institute, India
  • Taraprasad Das
    L. V. Prasad Eye Institute, India
  • Subhabrata Chakrabarti
    L. V. Prasad Eye Institute, India
  • Robyn H Guymer
    The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Melbourne, Victoria, Australia
    Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia
  • Margaret M DeAngelis
    The State University of New York, New York, United States
  • Paul N Baird
    The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Melbourne, Victoria, Australia
  • Takeshi Iwata
    Director of Molecular and Cellular Biology Division, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Yang Pan, None; Akiko Suga, None; Toru Noda, None; Inderjeet Kaur, None; Taraprasad Das, None; Subhabrata Chakrabarti, None; Robyn Guymer, None; Margaret DeAngelis, None; Paul Baird, None; Takeshi Iwata, None
  • Footnotes
    Support  This work has been supported by research grant to T.I. by the Japan Agency for Medical Research and Development (19ek0109282h0003), T.I by the Bilateral Program (2006-2007), Japan Society for the Promotion of Science (JSPS, 963552) with (DB and IK). Under the Bilateral Program (2006-2007), Department of Science & Technology and Australia-India Strategic Research Fund (AISRF) jointly funded through the Department of Biotechnology (DBT), Government of India (SC and IK) and the Department of Innovation, Industry, Science and Research (DIISR), Government of Australia (PNB and RHG). National Health & Medical Research Council of Australia (NHMRC) Research Fellowship 1138585 (PNB) and 1103013 (RHG). IK and SC would acknowledge the support of Retina consultants of LVPEI; Dr. Nazimul Hussain, Dr. Avinash Pathengay, Late Dr. Annie Mathai and Dr. Anjli Hussain for their help in recruitment of AMD patients and controls for this study. CERA receives Operational Infrastructure Support from the Victorian Government, Australia.
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 253. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yang Pan, Akiko Suga, Toru Noda, Inderjeet Kaur, Taraprasad Das, Subhabrata Chakrabarti, Robyn H Guymer, Margaret M DeAngelis, Paul N Baird, Takeshi Iwata; The ARMS2 insertion/deletion leads to systemic upregulation of secreted HTRA1 levels in the blood in AMD patients. Invest. Ophthalmol. Vis. Sci. 2021;62(8):253.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : AMD is a multi-factorial retinal disease, which affects millions of elderly people worldwide. We have previously demonstrated that the in/del sequence along with its downstream promoter region can significantly induce HTRA1 transcription in the transfected cell line 661W. Furthermore, our previous study of Htra1 transgenic mice driven by a CAG promoter showed a CNV-like phenotype after 12 months, while the use of a retinal pigment epithelial cell specific promoter by others has demonstrated polypoidal choroidal vasculopathy (PCV)-like phenotypes but not CNV. Therefore, we hypothesize that CNV is triggered by overexpression of HTRA1 in tissues outside of the eye. Here, we analyze the HTRA1 concentration in blood to correlate secretion of HTRA1 with the in/del in AMD.

Methods : Quantitative RT-PCR was performed to identify the HTRA1/Htra1 mRNA level across different human and mouse tissues, respectively. PCR and direct sequencing were performed to identify indel genotype in human samples from Japan, India, Australia, and the USA. To compare allelic or genotypic frequencies, the Chi-square test was used in additive models of each case group with controls. To identify the HTRA1 concentration in these blood samples (including serum and plasma), the ELISA was performed. The expression vector with the indel-HTRA1 was transfected into 661W, COS-7, and HEK-293 cells to observe HTRA1 secretion by ELISA. Moreover, ELISA was also performed in iPSCs derived from AMD patients.

Results : HTRA1/Htra1 was ubiquitously expressed across different tissues in both human and mice. Overexpression of Htra1 in mice demonstrated increased Htra1 protein serum concentration. Comparison of AMD patients with controls showed a significantly increased HTRA1 concentration in blood of AMD patients. Moreover, the increased secretion of HTRA1 protein was observed in the in/del-HTRA1 transfected cells and iPSCs derived from AMD patients. Furthermore, the HTRA1 protein blood level rises progressively with age in controls but remains high in AMD patients.

Conclusions : The in/del genotype is associated with AMD leading to an increase of HTRA1 secretion. The HTRA1 blood level is significantly higher in AMD patients with GA or CNV than age-matched controls, strongly suggesting that AMD is triggered by systemic increases of HTRA1 reaching the retinal choroidal capillaries through the bloodstream.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×